557 documents

Read All
15:53 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Patient sample and rabbit studies suggest estradiol could help treat neurobehavioral disorders associated with defects in interneuron development resulting from preterm birth. In postmortem brain samples from preterm to full-term infants (20-40 gestational weeks),...
Read More
17:24 , Aug 17, 2018 |  BC Week In Review  |  Company News

BioMotiv, Cure Network developing inhibitory interneuron small molecules

BioMotiv LLC (Cleveland, Ohio) partnered with Cure Network Dolby Acceleration Partners LLC (CNDAP) to develop small molecules that improve the function of inhibitor interneurons to treat neurological disorders, including Dravet syndrome, other epilepsies and Alzheimer’s...
Read More
19:10 , May 8, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy An in vitro differentiation protocol could generate V2a interneurons from HPSCs for use as cell therapies to treat SCI. The protocol had three steps: treating HPSCs with two tool compounds that inhibit SMAD...
Read More
23:36 , Apr 25, 2017 |  BC Extra  |  Clinical News

Interneuron strategy could lead to cell therapy for SCI

A team led by scientists at the Gladstone Institutes is the first to develop a cell culture strategy to generate V2a interneurons from human pluripotent stem cells (hPSCs), which could be used as a cell...
Read More
08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Mouse model of Tourette's syndrome

Disease models TECHNOLOGY: Transgenics and knockouts Mice with depletion of large cholinergic interneurons in the dorsolateral striatum could be useful as a model of Tourette's syndrome. In mice, injection of a cholinergic neuron-targeted virus expressing diphtheria toxin...
Read More
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Schizophrenia Not applicable Mouse studies suggest transplantation of hippocampal g-aminobutyric acid (GABA)-containing interneurons could help treat schizophrenia....
Read More
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Actin a2 smooth aorta muscle (ACTA2; a-SMA); smoothened (SMO); sonic hedgehog homolog (SHH) Studies in...
Read More
08:00 , Feb 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Epilepsy Estrogen receptor Mouse studies suggest estradiol or related drugs could be...
Read More
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Interneuron regulatory update

IPIC submitted an NDA to the FDA for CerAxon citicoline to treat ischemic stroke. The NDA is based on Phase III results announced last summer (see BioCentury Extra, July 16). Interneuron Pharmaceuticals Inc. (IPIC), Lexington,...
Read More
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Interneuron metabolic, neurological news

Shapiro Haber & Urmy LLP (Boston, Mass.) filed in the U.S. District Court for the District of Massachusetts a class action lawsuit against IPIC and its CEO, Glenn Cooper. The suit, filed on behalf of...
Read More